Recent Posts
Connect with:
Thursday / May 30.
HomeminewsGlaukos Acquires Dose Medical

Glaukos Acquires Dose Medical

Glaukos has aquired Dose Medical Corporation, a company that is developing multiple micro-invasive, bioerodible, sustained-release drug delivery platforms designed to be used in the treatment of various retinal diseases, including age-related macular degeneration and diabetic macular oedema.

Glaukos states that it “is leveraging its platform technologies to build a comprehensive and proprietary portfolio of micro-scale injectable therapies”. Glaukos launched its first MIGS device, the iStent, in 2012 and the iStent Inject in 2018.